2022/2020

12/20/2022

On 20 December 2022, the Düsseldorf Regional Court (Landgericht Düsseldorf) granted a preliminary injunction in favor of Grünenthal against two generic companies for commercialization of generic versions of Palexia^® retard in Germany. The generic companies are 1A Pharma and Ratiopharm.

5/5/2022

In February 2021, Grünenthal initiated a voluntary recall of all batches of Palexia^® 20 mg/ml oral solution and Palexia® 4 mg/ml oral solution due to a bacterial contamination in some batches. We have now received full approval to reintroduce these products back to the market.

2/7/2022

Grünenthal considers the outbreak and spread of Covid-19 to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees. We work to ensure an uninterrupted supply of our medicines for patients and supporting communities with curbing the Covid-19 outbreak.

11/27/2021

On the occasion of 60 years after the market withdrawal of Thalidomide, Dr. Michael Wirtz, shareholder of Grünenthal, apologised to those affected and their families on behalf of his family. As company, we welcome this step.

2/16/2021

In 2019, Grünenthal entered into a partnership with Mesoblast, a world leader in cellular medicines, to develop the investigational medicine MPC-06-ID, an innovative cell therapy for patients who suffer from chronic low back pain associated with degenerative disc disease, and who have exhausted conservative treatment options.

2/1/2021

As a science-driven company, it is our commitment to provide safe and effective oral contraceptives so that women are in a position to make their own decision and choices about their reproductive health.

10/19/2020

Grünenthal has issued notice to AcelRx Pharmaceuticals, Inc. to terminate the supply license agreement for Zalviso™.

6/30/2020

Grünenthal issued notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic® (lesinurad)¹ and Duzallo® (lesinurad and allopurinol, currently not marketed)² for the treatment of chronic hyperuricaemia in adults with gout, who have not achieved target serum uric acid levels with an adequate dose of a Xanthine Oxidase Inhibitor (XOI) alone, from the market in Europe. Zurampic and Duzallo will not be marketed in Latin America.

6/24/2020

The German federal parliament adopted an amendment to the Contergan Foundation Act on 19 June 2020, whereby benefits to Thalidomide victims, once granted, cannot be revoked. This includes the Thalidomide pension, which is paid by the Contergan Foundation. Only in special cases, such as deliberate deception, is it possible to withdraw benefits.